PHA UK co-founder and chair Dr Iain Armstrong has been named as a finalist in the ‘Innovations in your Specialty’ category of the Royal College of Nursing (RCN) Nursing Awards.
Iain, who also works as a nurse consultant at the Sheffield Pulmonary Vascular Disease Unit, has been recognised for his work in creating EmPHasis-10 - a clinical tool that measures quality of life for people with the rare disease pulmonary hypertension.
Designed as a simple questionnaire 11 years ago, it is now used around the world to help doctors and nurses understand how patients affected by this condition are responding to treatment. The tool addresses healthcare in a more holistic way by asking questions about mental wellbeing and general health, as well as about specific symptoms of the disease.
Iain will deliver a presentation about EmPHasis-10 to a specialist judging panel in July and the winner will be announced later next month.
He said: “It was a wonderful surprise to have been nominated for this award and to be named as a finalist is the icing on the cake. I am passionate about ensuring quality of life is prioritised for people with pulmonary hypertension - especially given the severity of symptoms that are experienced by those with this condition.”
PHA UK co-founder and chair Dr Iain Armstrong has been named as a finalist in the ‘Innovations in your Specialty’ category of the Royal College of Nursing (RCN) Nursing Awards.
28 June 2021The PHA UK has launched two pet-themed fundraisers to appeal to animal lovers looking to support people with PH this summer.
14 June 2021The PHA UK has launched new research to understand the impact of the COVID-19 pandemic on people affected by pulmonary hypertension.
7 June 2021A survey amongst the UK pulmonary hypertension community has shown overwhelming support for the development of a soft robotic heart that aims to reduce deaths from heart failure.
3 June 2021A new private Facebook group has been set up for those who have experienced loss due to pulmonary hypertension.
4 May 2021Our reaction to the announcement that those under 30 will be offered alternatives to the Oxford/AstraZeneca COVID-19 vaccine.
8 April 2021